Method and apparatus for providing a pharmacokinetic drug dosing regimen
Systems and methods providing a clotting factor VIII dosing regimen are disclosed. The systems and methods include determining an estimated pharmacokinetic profile of a patient using a Bayesian model of pharmacokinetic profiles of sampled patients. The systems and methods can determine a first dosing regimen for a first dosing interval including (i) a first dosage and (ii) a first therapeutic plasma protein level in the patient varying over time based at least upon the estimated pharmacokinetic profile. The systems and methods can determine a second dosing regimen for a second dosing interval including (i) a second dosage and (ii) a second therapeutic plasma protein level in the patient varying over time. The estimated pharmacokinetic profile can be adjusted based on previous patient treatments. Further, a user can select which days a dosage is to be applied such that the protein level does not fall below a target trough.
1. A method comprising:
determining, via a processor, an estimated pharmacokinetic (PK) profile of a patient using a Bayesian model of PK profiles of sampled patients;
determining, via the processor, a first dosing regimen for a first specified dosing interval in response to receiving at least one of a selected minimum therapeutic plasma protein level, a selected dosing interval, or a selected dosage amount of a therapeutic plasma protein, wherein:
the first dosing regimen is associated with a first time-varying therapeutic plasma protein level in the patient that is based at least upon the estimated PK profile, and
the at least one of the selected minimum therapeutic plasma protein level, the selected dosing interval, or the selected dosage amount is received at the processor via a graphical user interface (GUI) that includes fields for user input for adjusting at least one of the selected minimum therapeutic plasma protein level, the selected dosing interval, or the selected dosage amount; and
determining, via the processor, if the patient has a therapeutic plasma protein half-life greater than a predetermined threshold, wherein:
a first weighting factor is applied to the Bayesian model of PK profiles of sampled patients if the half-life of the patient is greater than the predetermined threshold, and
a second weighting factor, less than the first weighting factor, is applied to the Bayesian model of PK profiles of sampled patients if the half-life of the patient is less than the predetermined threshold.
2. The method of claim 1 further comprising:
determining, via the processor, a second dosing regimen for a second specified dosing interval associated with a second time-varying therapeutic plasma protein level in the patient that is based at least upon the estimated PK profile and in response to receiving a change to the at least one of the selected minimum therapeutic plasma protein level, the selected dosing interval, or the selected dosage amount of the therapeutic plasma protein, wherein the change to the at least one of the selected minimum therapeutic plasma protein level, the selected dosing interval, or the selected dosage amount is received at the processor via the GUI.
3. The method of claim 2 , wherein the first specified dosing interval is 48 hours and the second specified dosing interval is 72 hours.
4. The method of claim 1 , wherein the Bayesian model includes a two-compartment model having a first compartment corresponding to a time to metabolize the therapeutic plasma protein and a second compartment corresponding to a dose for achieving a certain amount of the therapeutic plasma protein within the patient.
5. The method of claim 1 , wherein the selected minimum therapeutic plasma protein level is a first minimum protein level, and wherein the method further comprises:
receiving, at the processor, a selection of a second minimum protein level greater that the first minimum protein level; and
determining, via the processor, a duration of time the first time-varying therapeutic plasma protein level in the patient is below the second minimum protein level; and
displaying, in the GUI, a graphical representation of the duration of time in conjunction with the display of the first dosing regimen.
6. The method of claim 5 , wherein the duration of time is further based on the time the first time-varying therapeutic plasma protein level is above the first minimum protein level.
7. The method of claim 1 , wherein the estimated PK profile is based at least on two blood samples collected from the patient after an infusion of therapeutic plasma protein.
8. A device comprising:
one or more processors; and
memory in communication with the one or more processors and having instructions stored thereon that, when executed, to cause a machine to:
prompt a user to enter at least one of a patient weight or age into fields of a graphical user interface (GUI) associated with the one or more processors;
determine an approximate pharmacokinetic (PK) profile of a patient based on a Bayesian model of PK profiles of sampled patients and a half-life of a therapeutic plasma protein within the patient;
determine a dosing regimen for the patient based upon the approximate PK profile of the patient, the dosing regimen including a first dosing interval, wherein the approximate PK profile of the patient is weighted based upon the half-life such that, if the half-life is greater than a predetermined threshold, the approximate PK profile of the patient is weighted more heavily than the PK profiles of sampled patients than if the half-life is less than the predetermined threshold;
modify the dosing regimen in response to receiving at least one of a specified dosing interval, a specified trough, or a specified dosage amount, wherein the specified dosing interval, the specified trough, or the specified dosage amount are received via fields in the GUI corresponding for changes to the specified dosing interval, the specified trough, or the specified dosage amount; and
display, within the GUI, a time-varying therapeutic plasma protein level based on the dosing regimen.
9. The device of claim 8 , wherein the instructions are further configured to cause the one or more processors to display a graphical representation of the time-varying therapeutic plasma protein level within the patient, including at least one indication of a dose of the therapeutic plasma protein being provided to the patient.
10. The device of claim 8 , wherein the instructions are further configured to cause the one or more processors to:
determine a first dosing regimen for a two-day dosing interval; and
determine a second dosing regimen for a three-day dosing interval.
11. The device of claim 8 , wherein the instructions are further configured to cause the one or more processors to:
receive, from the GUI, a minimum therapeutic target level and to display an amount of time the time-varying therapeutic plasma protein level is below the minimum therapeutic target level.
12. The device of claim 8 , wherein the instructions are further configured to cause the one or more processors to:
receive patient measurement blood data laboratory including a concentration of the therapeutic plasma protein within the patient after a time from when the therapeutic plasma protein was administered to the patient; and
modify the approximate PK profile based on the patient measurement blood laboratory data.
13. The device of claim 8 , wherein the half-life of the therapeutic plasma protein within the patient is determined based on at least two blood samples collected from the patient after an infusion of the therapeutic plasma protein.